{"id":"335750926_Combinatorial_Immunotherapy_Strategies_most_Gods_throw_Dice_but_fate_plays_Chess","authors":["Joseph Ciccolini","Dominique Barbolosi","Nicolas Andr√©","Sebastien Benzekry"],"meta":["September 2019Annals of Oncology 30(11)","DOI:10.1093/annonc/mdz297"],"references":["333294376_Combinatorial_Approaches_With_Checkpoint_Inhibitors_to_Enhance_Anti-tumor_Immunity","333068508_Immune_induction_strategies_in_metastatic_triple-negative_breast_cancer_to_enhance_the_sensitivity_to_PD-1_blockade_the_TONIC_trial","332789732_Combining_conventional_therapy_with_immunotherapy_A_risky_business","330853310_Combinatorial_Approach_to_Improve_Cancer_Immunotherapy_Rational_Drug_Design_Strategy_to_Simultaneously_Hit_Multiple_Targets_to_Kill_Tumor_Cells_and_to_Activate_the_Immune_System","326888312_Immunologically_effective_dose_A_practical_model_for_immuno-radiotherapy","321321646_Integrating_evolutionary_dynamics_into_treatment_of_metastatic_castrate-resistant_prostate_cancer","316654045_Mathematical_modeling_for_Phase_I_cancer_trials_A_study_of_metronomic_vinorelbine_for_advanced_non-small_cell_lung_cancer_NSCLC_and_mesothelioma_patients","299343056_Revisiting_dosing_regimen_using_PKPD_modeling_The_MODEL1_phase_III_trial_of_docetaxel_plus_epirubicin_in_metastatic_breast_cancer_patients","332023391_Atezolizumab_plus_bevacizumab_and_chemotherapy_in_non-small-cell_lung_cancer_IMpower150_key_subgroup_analyses_of_patients_with_EGFR_mutations_or_baseline_liver_metastases_in_a_randomised_open-label_ph","327085222_Combinations_of_Bevacizumab_With_Cancer_Immunotherapy"]}